The present application relates generally to treatment systems and methods with interrupt/resume capabilities for cooling subcutaneous lipid-rich cells.
Excess body fat, or adipose tissue, may be present in various locations of the body, including, for example, the thigh, buttocks, abdomen, knees, back, face, arms, chin, and other areas. Moreover, excess adipose tissue is thought to magnify the unattractive appearance of cellulite, which forms when subcutaneous fat protrudes into the dermis and creates dimples where the skin is attached to underlying structural fibrous strands. Cellulite and excessive amounts of adipose tissue are often considered to be unappealing. Moreover, significant health risks may be associated with higher amounts of excess body fat.
A variety of methods have been used to treat individuals having excess body fat and, in many instances, non-invasive removal of excess subcutaneous adipose tissue can eliminate unnecessary recovery time and discomfort associated with invasive procedures such as liposuction. Conventional non-invasive treatments for removing excess body fat typically include topical agents, weight-loss drugs, regular exercise, dieting, or a combination of these treatments. One drawback of these treatments is that they may not be effective or even possible under certain circumstances. For example, when a person is physically injured or ill, regular exercise may not be an option. Similarly, weight-loss drugs or topical agents are not an option when they cause an allergic or negative reaction. Furthermore, fat loss in selective areas of a person's body often cannot be achieved using general or systemic weight-loss methods.
Other methods designed to reduce subcutaneous adipose tissue include laser-assisted liposuction and mesotherapy. Newer non-invasive methods include applying radiant energy to subcutaneous lipid-rich cells via, e.g., radio frequency and/or light energy, such as described in U.S. Patent Publication No. 2006/0036300 and U.S. Pat. No. 5,143,063, or via, e.g., high intensity focused ultrasound (HIFU) radiation such as described in U.S. Pat. Nos. 7,258,674 and 7,347,855. Additional methods and devices for non-invasively reducing subcutaneous adipose tissue by cooling are disclosed in, e.g., Manstein et al. “A Novel Cryotherapy Method of Non-invasive, Selective Lipolysis” LasersSurg. Med. 40:S20 p 104 (2008), Manstein et al., “Selective Cryolysis: A Novel Method of Non-Invasive Fat Removal”, LasersSurg. Med. 40:595-604 (2008), U.S. Pat. No. 7,367,341 entitled “METHODS AND DEVICES FOR SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al.; U.S. Patent Publication No. 2005/0251120 entitled “METHODS AND DEVICES FOR DETECTION AND CONTROL OF SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al.; U.S. Patent Publication No. 2007/0198071 entitled “COOLING DEVICE FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS” to Ting et al.; U.S. Patent Publication No. 2007/0255362 entitled “CRYOPROTECTANT FOR USE WITH A TREATMENT DEVICE FOR IMPROVED COOLING FOR SUBCUTANEOUS LIPID-RICH CELLS” to Levinson et al.; U.S. Patent Publication No. 2008/0077201 entitled “COOLING DEVICE WITH FLEXIBLE SENSORS” to Levinson et al.; U.S. Patent Publication No. 2008/0077211 entitled “COOLING DEVICE HAVING A PLURALITY OF CONTROLLABLE COOLING ELEMENTS TO PROVIDE A PREDETERMINED COOLING PROFILE” to Levinson et al.; U.S. Patent Publication No. 2008/0287839 entitled “METHOD OF ENHANCED REMOVAL OF HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS AND TREATMENT APPARATUS HAVING AN ACTUATOR” to Rosen et al., filed May 18, 2007; U.S. patent application Ser. No. 11/777,992 entitled “SYSTEM FOR TREATING LIPID-RICH REGIONS” to Levinson et al., filed Jul. 13, 2007, the entire disclosures of which are incorporated herein by reference. Although the methods and devices disclosed in these publications and applications are promising, several improvements for enhancing the implementation of these methods and devices would be desirable.
In the drawings, identical reference numbers identify similar elements or acts. The sizes and relative positions of elements in the drawings are not necessarily drawn to scale. For example, the shapes of various elements and angles are not drawn to scale, and some of these elements are arbitrarily enlarged and positioned to improve drawing legibility. Further, the particular shapes of the elements as drawn are not intended to convey any information regarding the actual shape of the particular elements, and have been solely selected for ease of recognition in the drawings.
A. Overview
This document describes apparatus, systems, and methods for cooling subcutaneous adipose tissue. The term “subcutaneous tissue” generally refers to tissue lying beneath the dermis and includes subcutaneous fat, or adipose tissue, which primarily is composed of lipid-rich cells, or adipocytes. Several of the details set forth below are provided to describe the following embodiments and methods in a manner sufficient to enable a person skilled in the relevant art to practice, make, and use them. Several of the details and advantages described below, however, may not be necessary to practice certain embodiments and methods of the invention. Additionally, the invention may include other embodiments and methods that are within the scope of the claims but are not described in detail.
Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the occurrences of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. The headings provided herein are for convenience only and do not limit or interpret the scope or meaning of the claimed invention.
B. Suitable Treatment System
The treatment system 100 is suitable for treating a subject's subcutaneous adipose tissue, such as by cooling. The term “subcutaneous tissue” means tissue lying beneath the dermis and includes subcutaneous fat, or adipose tissue, which primarily is composed of lipid-rich cells, or adipocytes. When cooling subcutaneous tissue to a temperature lower than 37° C., subcutaneous lipid-rich cells can selectively be affected, or reduced. In general, the epidermis and dermis of the patient 101 lack lipid-rich cells compared to the underlying lipid-rich cells forming the adipose tissue. Because non-lipid-rich cells usually can withstand colder temperatures better than lipid-rich cells, the subcutaneous lipid-rich cells can selectively be reduced or affected without affecting the non-lipid-rich cells in the dermis, epidermis and other surrounding tissue. In some embodiments, the treatment system 100 can apply cooling temperatures to the skin of the patient in a range of from about −20° C. to about 20° C. In other embodiments, the cooling temperatures can be from about −20° C. to about 10° C., from about 0° C. to about 20° C., from about −15° C. to about 5° C., from about −5° C. to about 15° C., or from about −10° C. to about 0° C.
Without being bound by theory, the selective effect of cooling on lipid-rich cells is believed to result in, for example, membrane disruption, shrinkage, disabling, destroying, removing, killing, or another method of lipid-rich cell alteration. Such alteration is believed to be an intermediate and/or final result of one or more mechanisms acting alone or in combination. It is thought that such mechanism or mechanisms trigger an apoptotic cascade, which is believed to be the dominant form of lipid-rich cell death by non-invasive cooling.
Apoptosis, also referred to as “programmed cell death”, is a genetically-induced death mechanism by which cells self-destruct without incurring damage to surrounding tissue. An ordered series of biochemical events induce cells to morphologically change. These changes include cellular blebbing, loss of cell membrane asymmetry and attachment, cell shrinkage, chromatin condensation, and chromosomal DNA fragmentation. Injury via an external stimulus, such as cold exposure, is one mechanism that can induce apoptosis in cells. Nagle, W. A., Soloff, B. L., Moss, A. J. Jr., Henle, K. J. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures” Cryobiology 27, 439-451 (1990).
One aspect of apoptosis, in contrast to cellular necrosis (a traumatic form of cell death causing local inflammation), is that apoptotic cells express and display phagocytic markers on the surface of the cell membrane, thus marking the cells for phagocytosis by, for example, macrophages. As a result, phagocytes can engulf and remove the dying cells (e.g., the lipid-rich cells) without eliciting an immune response. Temperature exposures that elicit these apoptotic events in lipid-rich cells may contribute to long-lasting and/or permanent reduction and reshaping of subcutaneous adipose tissue.
Without being bound by theory, one mechanism of apoptotic lipid-rich cell death by cooling is believed to involve localized crystallization of lipids within the adipocytes at temperatures that do not induce crystallization in non-lipid-rich cells. The crystallized lipids may selectively injure these cells, inducing apoptosis (and may also induce necrotic death if the crystallized lipids damage or rupture the bilayer lipid membrane of the adipocyte). Another mechanism of injury involves the lipid phase transition of those lipids within the cell's bilayer lipid membrane, which results in membrane disruption, thereby inducing apoptosis. This mechanism is well-documented for many cell types and may be active when adipocytes, or lipid-rich cells, are cooled. Mazur, P., “Cryobiology: the Freezing of Biological Systems” Science, 68: 939-949 (1970); Quinn, P. J., “A Lipid Phase Separation Model of Low Temperature Damage to Biological Membranes” Cryobiology, 22: 128-147 (1985); Rubinsky, B., “Principles of Low Temperature Preservation” Heart Failure Reviews, 8, 277-284 (2003). Other yet-to-be understood apoptotic mechanisms may exist, based on the relative sensitivity of lipid-rich cells to cooling compared to non-lipid rich cells.
In addition to the apoptotic mechanisms involved in lipid-rich cell death, local cold exposure may induce lipolysis (i.e., fat metabolism) of lipid-rich cells. For example, cold stress has been shown to enhance rates of lipolysis from that observed under normal conditions which serves to further increase the volumetric reduction of subcutaneous lipid-rich cells. Vallerand, A. L., Zamecnik. J., Jones, P. J. H., Jacobs, I. “Cold Stress Increases Lipolysis, FFA Ra and TG/FFA Cycling in Humans” Aviation, Space and Environmental Medicine 70, 42-50 (1999).
In various embodiments, the system 100 includes a controller, a computing device, a data acquisition device, a treatment unit, and one or more applicators. The system can employ these components in various embodiments to receive a selection of a treatment profile and apply the selected treatment using an applicator.
An applicator, such as applicator 105, is a component of the system 100 that cools a region of a subject 101, such as a human or animal (i.e., “patient”). Various types of applicators may be applied during treatment, such as a vacuum applicator, a belt applicator (either of which may be used in combination with a massage or vibrating capability), and so forth. Each applicator may be designed to treat identified portions of the patient's body, such as chin, cheeks, arms, pectoral areas, thighs, calves, buttocks, abdomen, “love handles”, back, and so forth. For example, the vacuum applicator may be applied at the back region, and the belt applicator can be applied around the thigh region, either with or without massage or vibration. Exemplary applicators are described in, e.g., commonly assigned U.S. Patent Publication Nos. 2007/0198071, 2008/0077201, 2008/0077211, and 2008/0287839.
In further embodiments, the system 100 may also include a patient protection device (not shown) incorporated into or configured for use with the applicator that prevents the applicator from directly contacting a patient's skin and thereby reducing the likelihood of cross-contamination between patients, minimizing cleaning requirements for the applicator. The patient protection device may also include or incorporate various storage, computing, and communications devices, such as a radio frequency identification (RFID) component, allowing for example, monitoring and/or metering usage as described in U.S. patent application Ser. No. 11/777,992; U.S. patent application Ser. No. 11/777,995, entitled “LIMITING USE OF DISPOSABLE SYSTEM PATIENT PROTECTION DEVICES” to Levinson et al., filed Jul. 13, 2007; U.S. patent application Ser. No. 11/777,999, entitled “MANAGING SYSTEM TEMPERATURE TO REMOVE HEAT FROM LIPID-RICH REGIONS” to Levinson et al., filed Jul. 13, 2007; U.S. patent application Ser. No. 11/778,001, entitled “USER INTERFACES FOR A SYSTEM THAT REMOVES HEAT FROM LIPID-RICH REGIONS” to Levinson et al., filed Jul. 13, 2007; and U.S. patent application Ser. No. 11/778,003, entitled “SECURE SYSTEMS FOR REMOVING HEAT FROM LIPID-RICH REGIONS” to Levinson et al., filed Jul. 13, 2007, the entire disclosures of which are incorporated herein by reference. Exemplary patient protection devices are described in commonly assigned U.S. Patent Publication No. 2008/0077201.
In the present example, the system 100 can further include a treatment unit 106 and supply and return fluid lines 108a-b between the treatment device 104 and the treatment unit 106. A treatment unit 106 is a device that, based on variable power input, can increase or decrease the temperature at a connected treatment device 104 that in turn may be attached to or incorporated into the applicator 105. The treatment unit 106 can remove heat from a circulating coolant to a heat sink and provide a chilled coolant to the treatment device 104 via the fluid lines 108a-b. Alternatively, treatment unit 106 can circulate warm coolant to the treatment device 104 during periods of warming. Examples of the circulating coolant include water, glycol, synthetic heat transfer fluid, oil, a refrigerant, and/or any other suitable heat conducting fluid. The fluid lines 108a-b can be hoses or other conduits constructed from polyethylene, polyvinyl chloride, polyurethane, and/or other materials that can accommodate the particular circulating coolant. The treatment unit 106 can be a refrigeration unit, a cooling tower, a thermoelectric chiller, or any other device capable of removing heat from a coolant. Alternatively, a municipal water supply (e.g., tap water) can be used in place of the treatment unit 106. One skilled in the art will recognize that there are a number of other cooling technologies that could be used such that the treatment unit or chiller need not be limited to those described herein.
In this example, the treatment device 104 includes at least one applicator 105 and at least one treatment unit 106. The applicator 105 can provide mechanical energy to create a vibratory, massage, and/or pulsatile effect. The applicator 105 can include one or more actuators, such as, motors with eccentric weight, or other vibratory motors such as hydraulic motors, electric motors, pneumatic motors, solenoids, other mechanical motors, piezoelectric shakers, and so on, to provide vibratory energy to the treatment site. Further examples include a plurality of actuators for use in connection with a single treatment device 104 and/or applicator 105 in any desired combination. For example, an eccentric weight actuator can be associated with one treatment device 104 or applicator 105, while a pneumatic motor can be associated with another section of the same treatment device or applicator. This, for example, would give the operator of the treatment system 100 options for differential treatment of lipid rich cells within a single region or among multiple regions of the subject 101. The use of one or more actuators and actuator types in various combinations and configurations with a treatment device 104 or applicator 105 may be possible.
The treatment device 104 can include one or more heat exchanging units. The heat exchanging unit can be a Peltier-type thermoelectric element, and the treatment device 104 can have multiple individually controlled heat exchanging units (e.g., between 1 and 50, between 10 and 45; between 15 and 21, approximately 100, etc.) to create a custom spatial cooling profile and/or a time-varying cooling profile. Each custom treatment profile can include one or more segments, and each segment can include a specified duration, a target heat flux or temperature, and control parameters for features such as vibration, massage, vacuum, and other treatment modes. Treatment devices having multiple individually controlled heat exchanging units are described in commonly assigned U.S. Patent Publication No. 2008/0077211. Embodiments of a treatment device 104 usable with the treatment system 100 are described in more detail below with reference to
The system 100 can further include a power supply 110 and a controller 114 operatively coupled to the treatment device 104 and the applicator 105. In one embodiment, the power supply 110 can provide a direct current voltage to the thermoelectric treatment device 104 and/or the applicator 105 to remove heat from the subject 101. The controller 114 can monitor process parameters via sensors (not shown) placed proximate to the treatment device 104 via a control line 116 to, among other things, adjust the heat removal rate based on the process parameters. The controller 114 can further monitor process parameters to adjust the applicator 105 based on treatment parameters, such as treatment parameters defined in a custom treatment profile or patient-specific treatment plan.
The controller 114 can exchange data with the applicator 105 via an electrical line 112 or, alternatively, via a wireless or an optical communication link. Note that control line 116 and electrical line 112 are shown in
The controller 114 can include any processor, Programmable Logic Controller, Distributed Control System, secure processor, and the like. A secure processor can be implemented as an integrated circuit with access-controlled physical interfaces; tamper resistant containment; means of detecting and responding to physical tampering; secure storage; and shielded execution of computer-executable instructions. Some secure processors also provide cryptographic accelerator circuitry. Secure storage may also be implemented as a secure flash memory, secure serial EEPROM, secure field programmable gate array, or secure application-specific integrated circuit.
In another aspect, the controller 114 can receive data from an input device 118 (shown as a touch screen), transmit data to an output device 120, and/or exchange data with a control panel (not shown). The input device 118 can include a keyboard, a mouse, a stylus, a touch screen, a push button, a switch, a potentiometer, a scanner, or any other device suitable for accepting user input. The output device 120 can include a display or touch screen, a printer, a medium reader, an audio device, any combination thereof, and any other device or devices suitable for providing user feedback. In the embodiment of
In operation, and upon receiving input to start a treatment protocol, the controller 114 can cause the applicator 105 to cycle through each segment of a prescribed treatment plan. In so doing, the applicator 105 applies power to one or more treatment devices 104, such as thermoelectric coolers (e.g., TEC “zones”), to begin a cooling or heating cycle and, for example, activate features or modes such as vibration, massage, vacuum, etc. Using sensors (not shown) proximate to the one or more treatment devices 104, the patient's skin, a patient protection device, or other locations or combinations thereof, the controller 114 determines whether a temperature or heat flux that is sufficiently close to the target temperature or heat flux has been reached. It will be appreciated that while a region of the body (e.g., adipose tissue) has been cooled or heated to the target temperature or by a target heat flux, in actuality that region of the body may be close but not equal to the target temperature, e.g., because of the body's natural heating and cooling variations. Thus, although the system may attempt to heat or cool to the target temperature or by a target heat flux, a sensor may measure a sufficiently close temperature. If the target temperature has not been reached, power can be increased or decreased to change heat flux, as needed, to maintain the target temperature. When the prescribed segment duration expires, the controller 114 may apply the treatment parameters (e.g., heat flux or duration) indicated in the next treatment profile segment. In some embodiments, heat flux or temperature can be controlled using a variable other than, or in addition to, power.
During treatment, the treatment process may be interrupted. As used herein, the word “interrupted” generally refers to being in a state in which the treatment process may not safely and/or effectively proceed. For example, the treatment process may be interrupted when the applicator 105 is detached from the patient. In another example, the treatment process may be interrupted when the sensors (not shown) indicate freezing of the adipose tissue or when the treatment quality is unsatisfactory. In a further example, an operator or the patient may pause the treatment process using, e.g., the input device 118. In yet further examples, the treatment process may be interrupted based on other suitable conditions.
The interrupted treatment may cause operational difficulties and/or safety concerns for the patient. For example, if the operator restarts the treatment process from the initial stages of the treatment plan, the additional cooling or heating may be excessive to injure the adipose tissue of the patient. If the operator simply continues the treatment process, the adipose tissue of the patient may be insufficiently cooled or heated because of blood circulation and/or other physiological activities of the patient during the period of treatment interruption. As a result, the treatment process may not achieve the desired effect. Several embodiments of the treatment system 100 can at least reduce the impact of such interruptions by monitoring for an interruption and performing a recovery process to compensate for the interruption, as described in more detail below with reference to
Although a noninvasive applicator is illustrated and discussed herein, minimally invasive applicators may also be employed in connection with a noninvasive applicator. In such a case, the applicator and patient protection device may be integrated. As an example, a cryoprobe that may be inserted directly into the subcutaneous adipose tissue to cool or freeze the tissue is an example of such a minimally invasive applicator. Cryoprobes manufactured by, e.g., Endocare, Inc., of Irvine, Calif. are suitable for such applications. This patent application incorporates by reference U.S. Pat. No. 6,494,844, entitled “DEVICE FOR BIOPSY AND TREATMENT OF BREAST TUMORS”; U.S. Pat. No. 6,551,255, entitled “DEVICE FOR BIOPSY OF TUMORS”; U.S. Patent Publication No. 2007/0055173, entitled “ROTATIONAL CORE BIOPSY DEVICE WITH LIQUID CRYOGEN ADHESION PROBE”; U.S. Pat. No. 6,789,545, entitled “METHOD AND SYSTEM FOR CRYOABLATING FIBROADENOMAS”; U.S. Patent Publication No. 2004/0215294, entitled “CRYOTHERAPY PROBE”; U.S. Pat. No. 7,083,612, entitled “CRYOTHERAPY SYSTEM”; U.S. Patent Publication No. 2005/0261753, entitled “METHODS AND SYSTEMS FOR CRYOGENIC COOLING”, and U.S. patent application Ser. No. 11/933,066, entitled “METHOD AND APPARATUS FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS OR TISSUE” to Ebbers et al., filed Oct. 31, 2007.
In certain embodiments, the interface layer 220 of the treatment device 104 may include a sleeve for contacting the patient's skin 230. The sleeve may include a first sleeve portion (not shown) and a second sleeve portion (not shown) extending from the first sleeve portion. The first sleeve portion may contact and/or facilitate the contact of the treatment device 104 with the patient's skin 230. The second sleeve portion may be an isolation layer extending from the first sleeve portion. The second sleeve portion may be constructed from latex, rubber, nylon, Kevlar®, or other substantially impermeable or semi-permeable material. The second sleeve portion may prevent contact between the patient's skin 230 and the heat exchanging plates, among other things. Further details regarding a suitable sleeve may be found in U.S. Patent Publication No. 2008/0077201.
In other embodiments, the treatment device 104 may include a belt that assists in forming a contact between the treatment device 104 (such as via an interface layer 220) and the patient's skin 230. For example, the treatment device 104 may include retention devices (not shown) coupled to a frame. The retention devices may be rotatably connected to the frame by a plurality of coupling elements that may be, for example, pins, ball joints, bearings, or other type of rotatable joints. Alternatively, the retention devices may be rigidly affixed to the end portions of heat exchanging element housings. Further details regarding a suitable belt device may be found in U.S. Patent Publication No. 2008/0077211.
In further embodiments, the treatment device 104 may include a vacuum (not shown) that assists in forming a contact between the treatment device 104 (such as via the interface layer 220) and the patient's skin 230. For example, the treatment device 104 may provide mechanical energy to a treatment region. Imparting mechanical vibratory energy to the patient's tissue by repeatedly applying and releasing a vacuum to the subject's tissue, for instance, creates a massage action during treatment. Further details regarding a vacuum type device may be found in U.S. Patent Application Publication No. 2008/0287839.
C. Computing System Software Modules
In operation, the input module 302 accepts an operator input 319, such as process setpoint (e.g., a target heat flux or temperature) and control selections (e.g., a resume/terminate selection), and communicates the accepted information or selections to other components for further processing. The database module 304 organizes records, including treatment profiles 312, lookup tables 314, and alarms 316, and facilitates storing and retrieving of these records to and from a database 301. The treatment profiles 312 may include various therapies for treating different areas of the subject 101 (
The process module 306 generates control variables based on sensor readings 318 from sensors (e.g., the temperature measurement components 217 and 227 of
The sensing module 330 is configured to receive and convert the sensor readings 318 into parameters in desired units. For example, the sensing module 330 may receive the sensor readings 318 as electrical signals (e.g., a voltage or a current) and convert the electrical signals into instant temperatures in Celsius. In another example, the sensing module 330 may convert the electrical signals into an oxygen depletion level in the treated area as an indicator of hypoxia or ischemia. The sensing module 330 may have routines including, for example, linear interpolation, logarithmic interpolation, data mapping, or other routines to associate the sensor readings 318 to parameters in desired units.
The calculation module 336 may include routines configured to perform various types of calculation to facilitate operation of other modules. For example, the calculation module 336 may include counters, timers, and/or other suitable accumulation routines for deriving an elapsed time of treatment (t), an elapsed time since an interruption (τ), and/or other parameters associated with the interruption. Further, the calculation module 336 may include routines configured to calculate tissue temperatures at different times during treatment based on temperature parameters, heat flux parameters, and/or other suitable parameters.
In certain embodiments, the calculation module 336 may also include a computation routine for deriving an interruption temperature (Tinterrupt) of the adipose tissue based on the measured temperatures from at least one of the sensors 217 and 227 according to the following formula:
Tinterrupt=Toe−kt (Equation I)
where To is an initial temperature of the adipose tissue (e.g., 37° C.) and k is a time constant associated with cooling the adipose tissue. The cooling time constant k may be empirically derived for a particular interface temperature (e.g., 0° C.) between the cooling plate 210 (
In other embodiments, the calculation module 336 may also include another computation routine for deriving a rewarming temperature (Trewarm) of the adipose tissue after the interruption according to the following formula:
Trewarm=Tinterrupte−mτ (Equation II)
where m is a time constant associated with rewarming the adipose tissue. The rewarming time constant m may also be empirically derived for a particular ambient temperature (e.g., 25° C.) by performing an exponential curve fitting on a tissue temperature versus time plot (e.g., the plot shown in
In further embodiments, the calculation module 336 may include a lookup routine to derive the interruption temperature (Tinterrupt) and/or the rewarming temperature (Trewarm) of the adipose tissue based on the lookup tables 314 stored in the database 301 or plots of temperature versus time for cooling and/or rewarming of the adipose tissue. Examples of such temperature versus time plots for cooling and rewarming are shown in
In yet further embodiments, thermal modeling of different tissue and/or applicator geometries may result in different equations for deriving the interruption temperature of Equation I (Tinterrupt) and/or the rewarming temperature of Equation II (Trewarm). Moreover, even though the foregoing description is directed toward a process for cooling the adipose tissue, in other embodiments, the calculation module 336 may also include other suitable computation routines for calculating the interruption temperature and/or other parameters of the adipose tissue during a process for heating, or a combination of heating and cooling the adipose tissue.
In yet further embodiments, the calculation module 336 may also be configured to derive a rate of change for the interface temperature according to the following formula:
where Ti+1 is the temperature record number i+1, Ti is the previous temperature record, and Δt is the time difference between the two temperature records. The calculation module 336 may be configured to derive a rate of change of the temperature of the adipose tissue in a similar fashion.
The calculation module 336 may also be configured to derive a profile for a recovery process in response to the interruption. For example, the calculation module 336 may include a computation routine for calculating an amount of heat (Q) that must be removed from the adipose tissue to return the adipose tissue to the temperature at the time of the interruption as follows:
Q=ρVCP(Trewarm−Tinterrupt) (Equation IV)
where ρ is the density of the adipose tissue (e.g., about 918 kg/m3); V is a volume of the adipose tissue that approximately corresponds to a cross-sectional area of the cooling plate 210 and a thickness of the adipose tissue (e.g., about 0.1 m to about 0.2 m); and CP is the specific heat capacity of the adipose tissue (e.g., about 3.5 kJ/kg ° C.).
The density and specific heat capacity of the adipose tissue may empirically be determined. In certain embodiments, the operator may adjust the thickness of the adipose tissue, select a value from a list of available options, or enter a value determined by direct measurement involving, for example, ultrasound, calipers, electrical conductance, etc. In other embodiments, the thickness of the adipose tissue may automatically be set based on a particular treatment area (e.g., thighs, buttocks, etc.)
The calculation module 336 may also include another computation routine for deriving a desired cooling rate ({dot over (Q)}) for the recovery process as follows:
where π is a recovery duration. In certain embodiments, the operator may set the recovery duration (π) to any desired value with or without bounds. In other embodiments, the recovery duration (π) may be preselected and inaccessible to the operator.
In certain embodiments, the calculation module 336 may further include a computation routine for calculating an expected average rate of change in the temperature of the adipose tissue during the recovery period as follows:
In other embodiments, the expected rate of change may also be based on the interface temperature between the cooling plate 210 and the skin 230 of the subject 101.
The analysis module 332 may be configured to analyze parameters from the sensing module 330 and the calculation module 336 and to determine (1) whether an interruption has occurred; and (2) whether the treatment process may be resumed. The display module 310 may then receive the determined results for output to the operator. In certain embodiments, the analysis module 332 may indicate an interruption when the following conditions occur:
The analysis module 332 may also be configured to determine whether the treatment process may be resumed based on the following conditions:
The control module 334 may be configured to determine whether the recovery process should be initiated. In one embodiment, if the analysis module 332 indicates that an interruption has occurred and the treatment process may be resumed, the control module 334 may automatically initiate the recovery process. In another embodiment, the display module 310 may output the result from the analysis module 332 and prompt the operator for input. The input module 302 (
The control module 334 may also be configured to monitor parameters of the recovery process and adjust the recovery process based on the monitored parameters. In one embodiment, the control module 334 may monitor a rate of change of the temperature of the adipose tissue and/or the interface temperature during the recovery process. If the monitored rate of change is below the expected rate of change from Equation VI by a preselected amount (e.g., 25%), then the control module 334 may (1) increase a power output to the cooling plate 210 by a preselected amount or by a proportional-derivative-integral (PID) routine using the rate of change as a process variable; and/or (2) increase the recovery duration by a preselected amount (e.g., 3 minutes); otherwise, the control module 334 continues to monitor the recovery process. In other embodiments, the control module 334 may also monitor a heat flux, a thermal image, and/or other parameters of the recovery process.
D. Treatment Resumption Methods
As shown in
Another stage 504 of the method 500 may include detecting an interruption in the treatment process. In one embodiment, detecting the interruption may include accepting an input for pause from the operator and/or the subject 101 by the input module 302. In other embodiments, detecting an interruption may include continuously sensing an interface temperature between the cooling plate 210 and the skin 230 of the subject 101 with the sensing module 330, calculating a rate of change for the sensed temperature with the calculation module 336, and analyzing the calculated rate of change of the sensed temperature with the analysis module 332. In further embodiments, detecting an interruption may include detecting skin freezing, monitoring treatment quality, identifying movement of the treatment device 104 (
A determination is made at stage 505. If an interruption is not detected, the process reverts to continuing the treatment process at stage 502. If an interruption is detected, the process continues to another stage 506 for determining with the analysis module 332 whether the treatment process may be resumed. The calculation module 336 may then determine the accumulated elapsed time of treatment and accumulate the elapsed time of interruption by, for example, activating another internal timer or counter. If the treatment process may not be resumed, the process reverts to initiating another treatment process at stage 502, and the calculation module 336 may reset both the elapsed time of treatment and the elapsed time of interruption.
If the treatment process is determined to be resumable, in one embodiment, the method 500 includes another stage 508 in which a recovery process is performed in response to the interruption. Optionally, in another embodiment, the interruption and the determination that the treatment process may be resumed can be indicated to the operator via, e.g., the display 118 (
In one embodiment, performing the recovery process includes returning the adipose tissue to a condition (e.g., temperature) at least approximately equal to that at the time of the interruption. In other embodiments, if the interruption is detected based on tissue freezing, tissue overheating, and/or other suitable conditions, the adipose tissue may not be returned to a condition at least approximately equal to that at the time of interruption. Instead, performing the recovery process may include cooling, warming, and/or otherwise treating the adipose tissue and/or surrounding tissue based on suitable parameters to reduce the likelihood of injury. In yet other embodiments, performing the recovery process may include replacing the interface layer 220 with a new piece and pre-cooling the new interface layer 220 to a suitable temperature. Several embodiments of performing the recovery process are described in more detail below with reference to
After performing the recovery process at stage 508, the method 500 may also include continuing the interrupted treatment process at stage 510. In one embodiment, continuing the interrupted treatment process includes performing the remaining treatment operations according to the treatment profile. For example, if the treatment profile includes cooling the skin 230 of the subject 101 for a total of 30 minutes, and the elapsed treatment time is 10 minutes, continuing the interrupted treatment process includes cooling the skin 230 of the subject 101 for another 20 minutes after performing the recovery process. In other embodiments, continuing the interrupted treatment process may also include performing other suitable operations according to the treatment profile.
Another stage 604 of the method 508 may include performing recovery via, e.g., cooling the adipose tissue according to the determined recovery conditions by, for example, activating the power supply 110 (
A further stage 606 of the method 508 may include monitoring the recovery process. For example, in one embodiment, monitoring the recovery process may include sensing the interface temperature with at least one of the temperature measurement components 217 and 227, converting the sensed interface temperature with the sensing module 330, and calculating a rate of change for the interface temperature with the calculation module 336. In other embodiments, monitoring the recovery process may include monitoring other suitable parameters.
The analysis module 332 may then determine whether the recovery process is satisfactory based on the calculated rate of change of the interface temperature and/or other suitable parameters at stage 608. If the recovery process is not satisfactory, another stage 610 of the method 508 includes adjusting the recovery process with the control module 334, and the process reverts to cooling the adipose tissue at stage 604. If the recovery process is satisfactory, another determination is performed at stage 612 to decide whether the process should return. In one embodiment, the determined recovery conditions include a recovery time, and if the recovery time has not expired, the process reverts to cooling the adipose tissue; otherwise, the process returns. In other embodiments, the operator and/or the subject 101 may terminate the recovery process.
Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise,” “comprising,” and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense, that is to say, in a sense of “including, but not limited to.” Words using the singular or plural number also include the plural or singular number, respectively. When the claims use the word “or” in reference to a list of two or more items, that word covers all of the following interpretations of the word: any of the items in the list, all of the items in the list, and any combination of the items in the list.
The various embodiments described above may be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entireties. Aspects of the invention may be modified, if necessary, to employ treatment devices and actuators with a plurality of treatment units, thermally conductive devices with various configurations, and concepts of the various patents, applications, and publications to provide yet further embodiments of the invention.
These and other changes may be made to the invention in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the invention to the specific embodiments disclosed in the specification and the claims, but should be construed to include all cooling that operates in accordance with the claims. Accordingly, the invention is not limited by the disclosure, but instead its scope is to be determined entirely by the following claims.
The present application is a continuation of U.S. patent application Ser. No. 12/337,544, filed Dec. 17, 2008, now U.S. Pat. No. 8,603,073, the disclosure of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
681806 | Mignault | Sep 1901 | A |
889810 | Robinson | Jun 1908 | A |
2516491 | Swastek | Jul 1950 | A |
2726658 | Chessey | Dec 1955 | A |
2766619 | Tribus et al. | Oct 1956 | A |
2851602 | Cramwinckel et al. | Sep 1958 | A |
3093135 | Hirschhorn | Jun 1963 | A |
3132688 | Nowak | May 1964 | A |
3133539 | William et al. | May 1964 | A |
3282267 | Wiliam | Nov 1966 | A |
3502080 | Hirschhorn | Mar 1970 | A |
3587577 | Smirnov et al. | Jun 1971 | A |
3591645 | Selwitz | Jul 1971 | A |
3703897 | Mack et al. | Nov 1972 | A |
3710784 | Taylor | Jan 1973 | A |
3786814 | Armao | Jan 1974 | A |
3827436 | Stumpf et al. | Aug 1974 | A |
3942519 | Shock | Mar 1976 | A |
3948269 | Zimmer | Apr 1976 | A |
3986385 | Johnston et al. | Oct 1976 | A |
3993053 | Grossan | Nov 1976 | A |
4002221 | Buchalter | Jan 1977 | A |
4026299 | Sauder | May 1977 | A |
4140130 | Storm, III | Feb 1979 | A |
4149529 | Copeland et al. | Apr 1979 | A |
4178429 | Scheffer | Dec 1979 | A |
4202336 | van Gerven et al. | May 1980 | A |
4266043 | Fujii et al. | May 1981 | A |
4269068 | Molina | May 1981 | A |
4381009 | Del Bon et al. | Apr 1983 | A |
4396011 | Mack et al. | Aug 1983 | A |
4459854 | Richardson et al. | Jul 1984 | A |
4483341 | Witteles | Nov 1984 | A |
4528979 | Marchenko et al. | Jul 1985 | A |
4531524 | Mioduski | Jul 1985 | A |
4548212 | Leung | Oct 1985 | A |
4555313 | Duchane et al. | Nov 1985 | A |
4585002 | Kissin | Apr 1986 | A |
4603076 | Bowditch et al. | Jul 1986 | A |
4614191 | Perler | Sep 1986 | A |
4644955 | Mioduski | Feb 1987 | A |
4664110 | Schanzlin | May 1987 | A |
4700701 | Montaldi | Oct 1987 | A |
4718429 | Smidt et al. | Jan 1988 | A |
4741338 | Miyamae et al. | May 1988 | A |
4764463 | Mason et al. | Aug 1988 | A |
4802475 | Weshahy et al. | Feb 1989 | A |
4832022 | Tjulkov et al. | May 1989 | A |
4846176 | Golden | Jul 1989 | A |
4850340 | Onishi | Jul 1989 | A |
4869250 | Bitterly | Sep 1989 | A |
4880564 | Abel et al. | Nov 1989 | A |
4905697 | Heggs et al. | Mar 1990 | A |
4906463 | Cleary et al. | Mar 1990 | A |
4930317 | Klein | Jun 1990 | A |
4935345 | Guilbeau et al. | Jun 1990 | A |
4961422 | Marchosky et al. | Oct 1990 | A |
4962761 | Golden | Oct 1990 | A |
4990144 | Blott | Feb 1991 | A |
5007433 | Hermsdorffer et al. | Apr 1991 | A |
5018521 | Campbell | May 1991 | A |
5024650 | Hagiwara et al. | Jun 1991 | A |
5065752 | Sessions et al. | Nov 1991 | A |
5069208 | Noppel et al. | Dec 1991 | A |
5084671 | Miyata et al. | Jan 1992 | A |
5108390 | Potocky et al. | Apr 1992 | A |
5119674 | Nielsen et al. | Jun 1992 | A |
5139496 | Hed | Aug 1992 | A |
5143063 | Fellner | Sep 1992 | A |
5148804 | Hill et al. | Sep 1992 | A |
5158070 | Dory | Oct 1992 | A |
5169384 | Bosniak et al. | Dec 1992 | A |
5197466 | Marchosky et al. | Mar 1993 | A |
5207674 | Hamilton | May 1993 | A |
5221726 | Dabi et al. | Jun 1993 | A |
5264234 | Windhab et al. | Nov 1993 | A |
5277030 | Miller | Jan 1994 | A |
5314423 | Seney | May 1994 | A |
5327886 | Chiu | Jul 1994 | A |
5330745 | McDow | Jul 1994 | A |
5333460 | Lewis et al. | Aug 1994 | A |
5334131 | Omandam et al. | Aug 1994 | A |
5336616 | Livesey et al. | Aug 1994 | A |
5339541 | Owens | Aug 1994 | A |
5342617 | Gold | Aug 1994 | A |
5351677 | Kami et al. | Oct 1994 | A |
5358467 | Milstein et al. | Oct 1994 | A |
5362966 | Rosenthal et al. | Nov 1994 | A |
5363347 | Nguyen | Nov 1994 | A |
5372608 | Johnson | Dec 1994 | A |
5386837 | Sterzer | Feb 1995 | A |
5411541 | Bell et al. | May 1995 | A |
5427772 | Hagan | Jun 1995 | A |
5433717 | Rubinsky et al. | Jul 1995 | A |
5456703 | Beeuwkes, III | Oct 1995 | A |
5472416 | Blugerman et al. | Dec 1995 | A |
5486207 | Mahawili | Jan 1996 | A |
5497596 | Zatkulak | Mar 1996 | A |
5501655 | Rolt et al. | Mar 1996 | A |
5505726 | Meserol | Apr 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5507790 | Weiss et al. | Apr 1996 | A |
5514105 | Goodman, Jr. et al. | May 1996 | A |
5514170 | Mauch | May 1996 | A |
5516505 | McDow | May 1996 | A |
5531742 | Barken | Jul 1996 | A |
5562604 | Yablon et al. | Oct 1996 | A |
5571801 | Segall et al. | Nov 1996 | A |
5575812 | Owens et al. | Nov 1996 | A |
5603221 | Maytal et al. | Feb 1997 | A |
5628769 | Saringer et al. | May 1997 | A |
5634890 | Morris | Jun 1997 | A |
5634940 | Panyard | Jun 1997 | A |
5647051 | Neer | Jul 1997 | A |
5647868 | Chinn | Jul 1997 | A |
5650450 | Lovette et al. | Jul 1997 | A |
5651773 | Perry et al. | Jul 1997 | A |
5654279 | Rubinsky et al. | Aug 1997 | A |
5654546 | Lindsay | Aug 1997 | A |
5660836 | Knowlton | Aug 1997 | A |
5665053 | Jacobs | Sep 1997 | A |
5672172 | Zupkas | Sep 1997 | A |
5700284 | Owens et al. | Dec 1997 | A |
5725483 | Podolsky | Mar 1998 | A |
5733280 | Avitall | Mar 1998 | A |
5741248 | Stern et al. | Apr 1998 | A |
5746736 | Tankovich | May 1998 | A |
5755663 | Larsen et al. | May 1998 | A |
5755753 | Knowlton | May 1998 | A |
5755755 | Panyard | May 1998 | A |
5759182 | Varney et al. | Jun 1998 | A |
5759764 | Polovina | Jun 1998 | A |
5769879 | Richards et al. | Jun 1998 | A |
5785955 | Fischer | Jul 1998 | A |
5792080 | Ookawa et al. | Aug 1998 | A |
5800490 | Patz et al. | Sep 1998 | A |
5814040 | Nelson et al. | Sep 1998 | A |
5817050 | Klein | Oct 1998 | A |
5817149 | Owens et al. | Oct 1998 | A |
5817150 | Owens et al. | Oct 1998 | A |
5830208 | Muller | Nov 1998 | A |
5833685 | Tortal et al. | Nov 1998 | A |
5844013 | Kenndoff et al. | Dec 1998 | A |
5865841 | Kolen et al. | Feb 1999 | A |
5871524 | Knowlton | Feb 1999 | A |
5871526 | Gibbs et al. | Feb 1999 | A |
5885211 | Eppstein et al. | Mar 1999 | A |
5891617 | Watson et al. | Apr 1999 | A |
5895418 | Saringer et al. | Apr 1999 | A |
5901707 | Gon.cedilla.alves et al. | May 1999 | A |
5902256 | Benaron | May 1999 | A |
5919219 | Knowlton | Jul 1999 | A |
5944748 | Mager et al. | Aug 1999 | A |
5948011 | Knowlton | Sep 1999 | A |
5954680 | Augustine et al. | Sep 1999 | A |
5964092 | Tozuka et al. | Oct 1999 | A |
5964749 | Eckhouse et al. | Oct 1999 | A |
5967976 | Larsen et al. | Oct 1999 | A |
5980561 | Kolen et al. | Nov 1999 | A |
5986167 | Arteman et al. | Nov 1999 | A |
5989286 | Owens et al. | Nov 1999 | A |
5997530 | Nelson et al. | Dec 1999 | A |
6017337 | Pira et al. | Jan 2000 | A |
6023932 | Johnston et al. | Feb 2000 | A |
6032675 | Rubinsky | Mar 2000 | A |
6039694 | Larson et al. | Mar 2000 | A |
6041787 | Rubinsky | Mar 2000 | A |
6047215 | McClure et al. | Apr 2000 | A |
6049927 | Thomas et al. | Apr 2000 | A |
6051159 | Hao et al. | Apr 2000 | A |
6071239 | Cribbs et al. | Jun 2000 | A |
6074415 | Der Ovanesian | Jun 2000 | A |
6093230 | Johnson, III et al. | Jul 2000 | A |
6102885 | Bass | Aug 2000 | A |
6104952 | Tu et al. | Aug 2000 | A |
6104959 | Spertell et al. | Aug 2000 | A |
6106517 | Zupkas | Aug 2000 | A |
6113558 | Rosenschein et al. | Sep 2000 | A |
6113559 | Klopotek | Sep 2000 | A |
6113626 | Clifton et al. | Sep 2000 | A |
6120519 | Weber et al. | Sep 2000 | A |
6139544 | Mikus et al. | Oct 2000 | A |
6150148 | Nanda et al. | Nov 2000 | A |
6152952 | Owens et al. | Nov 2000 | A |
6171301 | Nelson et al. | Jan 2001 | B1 |
6180867 | Hedengren et al. | Jan 2001 | B1 |
6226996 | Weber et al. | May 2001 | B1 |
6241753 | Knowlton | Jun 2001 | B1 |
6264649 | Whitcroft et al. | Jul 2001 | B1 |
6273884 | Altshuler et al. | Aug 2001 | B1 |
6290988 | Van Vilsteren et al. | Sep 2001 | B1 |
6311090 | Knowlton | Oct 2001 | B1 |
6311497 | Chung et al. | Nov 2001 | B1 |
6312453 | Stefanile et al. | Nov 2001 | B1 |
6350276 | Knowlton | Feb 2002 | B1 |
6354297 | Eiseman | Mar 2002 | B1 |
6357907 | Cleveland et al. | Mar 2002 | B1 |
6375673 | Clifton et al. | Apr 2002 | B1 |
6377854 | Knowlton | Apr 2002 | B1 |
6377855 | Knowlton | Apr 2002 | B1 |
6381497 | Knowlton | Apr 2002 | B1 |
6381498 | Knowlton | Apr 2002 | B1 |
6387380 | Knowlton | May 2002 | B1 |
6401722 | Krag | Jun 2002 | B1 |
6405090 | Knowlton | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6425912 | Knowlton | Jul 2002 | B1 |
6426445 | Young et al. | Jul 2002 | B1 |
6430446 | Knowlton | Aug 2002 | B1 |
6430956 | Haas et al. | Aug 2002 | B1 |
6438424 | Knowlton | Aug 2002 | B1 |
6438954 | Goetz et al. | Aug 2002 | B1 |
6438964 | Giblin | Aug 2002 | B1 |
6453202 | Knowlton | Sep 2002 | B1 |
6458888 | Hood et al. | Oct 2002 | B1 |
6461378 | Knowlton | Oct 2002 | B1 |
6470216 | Knowlton | Oct 2002 | B1 |
6471693 | Carroll et al. | Oct 2002 | B1 |
6475211 | Chess et al. | Nov 2002 | B2 |
6478811 | Dobak, III et al. | Nov 2002 | B1 |
6494844 | Van Bladel et al. | Dec 2002 | B1 |
6497721 | Ginsburg et al. | Dec 2002 | B2 |
6508831 | Kushnir | Jan 2003 | B1 |
6514244 | Pope et al. | Feb 2003 | B2 |
6519964 | Bieberich | Feb 2003 | B2 |
6523354 | Tolbert | Feb 2003 | B1 |
6527765 | Kelman et al. | Mar 2003 | B2 |
6527798 | Ginsburg et al. | Mar 2003 | B2 |
6544248 | Bass | Apr 2003 | B1 |
6547811 | Becker et al. | Apr 2003 | B1 |
6548297 | Kuri-Harcuch et al. | Apr 2003 | B1 |
6551255 | Van Bladel et al. | Apr 2003 | B2 |
6551341 | Boylan et al. | Apr 2003 | B2 |
6551348 | Blalock et al. | Apr 2003 | B1 |
6551349 | Lasheras et al. | Apr 2003 | B2 |
6569189 | Augustine et al. | May 2003 | B1 |
6585652 | Lang et al. | Jul 2003 | B2 |
6592577 | Abboud et al. | Jul 2003 | B2 |
6605080 | Altshuler et al. | Aug 2003 | B1 |
6607498 | Eshel | Aug 2003 | B2 |
6620187 | Carson et al. | Sep 2003 | B2 |
6620188 | Ginsburg et al. | Sep 2003 | B1 |
6620189 | Machold et al. | Sep 2003 | B1 |
6623430 | Slayton et al. | Sep 2003 | B1 |
6626854 | Friedman et al. | Sep 2003 | B2 |
6632219 | Baranov et al. | Oct 2003 | B1 |
6635053 | Lalonde et al. | Oct 2003 | B1 |
6643535 | Damasco et al. | Nov 2003 | B2 |
6645162 | Friedman et al. | Nov 2003 | B2 |
6645229 | Matsumura et al. | Nov 2003 | B2 |
6645232 | Carson | Nov 2003 | B2 |
6648904 | Altshuler et al. | Nov 2003 | B2 |
6656208 | Grahn et al. | Dec 2003 | B2 |
6660027 | Gruszecki et al. | Dec 2003 | B2 |
6662054 | Kreindel et al. | Dec 2003 | B2 |
6682550 | Clifton et al. | Jan 2004 | B2 |
6685731 | Kushnir et al. | Feb 2004 | B2 |
6694170 | Mikus et al. | Feb 2004 | B1 |
6695874 | Machold et al. | Feb 2004 | B2 |
6697670 | Chomenky et al. | Feb 2004 | B2 |
6699237 | Weber et al. | Mar 2004 | B2 |
6699266 | Lachenbruch et al. | Mar 2004 | B2 |
6699267 | Voorhees et al. | Mar 2004 | B2 |
6718785 | Bieberich | Apr 2004 | B2 |
6741895 | Gafni et al. | May 2004 | B1 |
6743222 | Durkin et al. | Jun 2004 | B2 |
6746474 | Saadat | Jun 2004 | B2 |
6749624 | Knowlton | Jun 2004 | B2 |
6764493 | Weber et al. | Jul 2004 | B1 |
6764502 | Bieberich | Jul 2004 | B2 |
6789545 | Littrup et al. | Sep 2004 | B2 |
6795728 | Chornenky et al. | Sep 2004 | B2 |
6820961 | Johnson | Nov 2004 | B2 |
6821274 | McHale et al. | Nov 2004 | B2 |
6840955 | Ein | Jan 2005 | B2 |
6849075 | Bertolero et al. | Feb 2005 | B2 |
6878144 | Altshuler et al. | Apr 2005 | B2 |
6889090 | Kreindel | May 2005 | B2 |
6892099 | Jaafar et al. | May 2005 | B2 |
6904956 | Noel | Jun 2005 | B2 |
6918903 | Bass | Jul 2005 | B2 |
6927316 | Faries, Jr. et al. | Aug 2005 | B1 |
6942022 | Blangetti et al. | Sep 2005 | B2 |
6945942 | Van Bladel et al. | Sep 2005 | B2 |
6948903 | Ablabutyan et al. | Sep 2005 | B2 |
6969399 | Schock et al. | Nov 2005 | B2 |
7005558 | Johansson et al. | Feb 2006 | B1 |
7006874 | Knowlton et al. | Feb 2006 | B2 |
7022121 | Stern et al. | Apr 2006 | B2 |
7037326 | Lee et al. | May 2006 | B2 |
7054685 | Dimmer et al. | May 2006 | B2 |
7060061 | Altshuler et al. | Jun 2006 | B2 |
7077858 | Fletcher et al. | Jul 2006 | B2 |
7081111 | Svaasand et al. | Jul 2006 | B2 |
7083612 | Littrup et al. | Aug 2006 | B2 |
7096204 | Chen et al. | Aug 2006 | B1 |
7112712 | Ancell | Sep 2006 | B1 |
7115123 | Knowlton et al. | Oct 2006 | B2 |
7141049 | Stern et al. | Nov 2006 | B2 |
7183360 | Daniel et al. | Feb 2007 | B2 |
7189252 | Krueger | Mar 2007 | B2 |
7192426 | Baust et al. | Mar 2007 | B2 |
7204832 | Altshuler et al. | Apr 2007 | B2 |
7220778 | Anderson et al. | May 2007 | B2 |
7229436 | Stern et al. | Jun 2007 | B2 |
7258674 | Cribbs et al. | Aug 2007 | B2 |
7267675 | Stern et al. | Sep 2007 | B2 |
7276058 | Altshuler et al. | Oct 2007 | B2 |
7318821 | Lalonde et al. | Jan 2008 | B2 |
7331951 | Eshel et al. | Feb 2008 | B2 |
7347855 | Eshel et al. | Mar 2008 | B2 |
7367341 | Anderson et al. | May 2008 | B2 |
7532201 | Quistgaard et al. | May 2009 | B2 |
7572268 | Babaev | Aug 2009 | B2 |
7604632 | Howlett et al. | Oct 2009 | B2 |
7613523 | Eggers et al. | Nov 2009 | B2 |
7615016 | Barthe et al. | Nov 2009 | B2 |
7713266 | Elkins et al. | May 2010 | B2 |
7780656 | Tankovich | Aug 2010 | B2 |
7799018 | Goulko | Sep 2010 | B2 |
7824437 | Saunders | Nov 2010 | B1 |
7828831 | Tanhehco et al. | Nov 2010 | B1 |
7850683 | Elkins et al. | Dec 2010 | B2 |
7854754 | Ting et al. | Dec 2010 | B2 |
7862558 | Elkins et al. | Jan 2011 | B2 |
RE42277 | Jaafar et al. | Apr 2011 | E |
7938824 | Chornenky et al. | May 2011 | B2 |
7959657 | Harsy et al. | Jun 2011 | B1 |
7963959 | Da Silva et al. | Jun 2011 | B2 |
7967763 | Deem et al. | Jun 2011 | B2 |
7993330 | Goulko | Aug 2011 | B2 |
7998137 | Elkins et al. | Aug 2011 | B2 |
RE42835 | Chornenky et al. | Oct 2011 | E |
RE43009 | Chornenky et al. | Dec 2011 | E |
8133180 | Slayton et al. | Mar 2012 | B2 |
8133191 | Rosenberg et al. | Mar 2012 | B2 |
8192474 | Levinson | Jun 2012 | B2 |
8246611 | Paithankar et al. | Aug 2012 | B2 |
8275442 | Allison | Sep 2012 | B2 |
8285390 | Levinson et al. | Oct 2012 | B2 |
8333700 | Barthe et al. | Dec 2012 | B1 |
8337539 | Ting et al. | Dec 2012 | B2 |
8366622 | Slayton et al. | Feb 2013 | B2 |
8397518 | Vistakula et al. | Mar 2013 | B1 |
8414631 | Quisenberry et al. | Apr 2013 | B2 |
8433400 | Prushinskaya et al. | Apr 2013 | B2 |
8506486 | Slayton et al. | Aug 2013 | B2 |
8523775 | Barthe et al. | Sep 2013 | B2 |
8523791 | Castel | Sep 2013 | B2 |
8523927 | Levinson et al. | Sep 2013 | B2 |
8535228 | Slayton et al. | Sep 2013 | B2 |
8603073 | Allison | Dec 2013 | B2 |
8636665 | Slayton et al. | Jan 2014 | B2 |
8641622 | Barthe et al. | Feb 2014 | B2 |
8663112 | Slayton et al. | Mar 2014 | B2 |
8672848 | Slayton et al. | Mar 2014 | B2 |
8676332 | Fahey | Mar 2014 | B2 |
8690778 | Slayton et al. | Apr 2014 | B2 |
8690779 | Slayton et al. | Apr 2014 | B2 |
8690780 | Slayton et al. | Apr 2014 | B2 |
8702774 | Baker et al. | Apr 2014 | B2 |
8758215 | Legendre et al. | Jun 2014 | B2 |
8764693 | Graham et al. | Jul 2014 | B1 |
8834547 | Anderson et al. | Sep 2014 | B2 |
20010005791 | Ginsburg et al. | Jun 2001 | A1 |
20010007952 | Shimizu | Jul 2001 | A1 |
20010023364 | Ahn | Sep 2001 | A1 |
20010031459 | Fahy et al. | Oct 2001 | A1 |
20010039439 | Elkins et al. | Nov 2001 | A1 |
20010045104 | Bailey et al. | Nov 2001 | A1 |
20010047196 | Ginsburg et al. | Nov 2001 | A1 |
20020026226 | Ein | Feb 2002 | A1 |
20020032473 | Kushnir et al. | Mar 2002 | A1 |
20020049483 | Knowlton | Apr 2002 | A1 |
20020058975 | Bieberich | May 2002 | A1 |
20020062142 | Knowlton | May 2002 | A1 |
20020068338 | Nanda et al. | Jun 2002 | A1 |
20020082668 | Ingman | Jun 2002 | A1 |
20020103520 | Latham | Aug 2002 | A1 |
20020107558 | Clifton et al. | Aug 2002 | A1 |
20020117293 | Campbell | Aug 2002 | A1 |
20020120315 | Furuno et al. | Aug 2002 | A1 |
20020128648 | Weber et al. | Sep 2002 | A1 |
20020151830 | Kahn | Oct 2002 | A1 |
20020151887 | Stern et al. | Oct 2002 | A1 |
20020156509 | Cheung | Oct 2002 | A1 |
20020188286 | Quijano et al. | Dec 2002 | A1 |
20020198518 | Mikus et al. | Dec 2002 | A1 |
20030032900 | Ella | Feb 2003 | A1 |
20030044764 | Soane et al. | Mar 2003 | A1 |
20030055414 | Altshuler et al. | Mar 2003 | A1 |
20030069618 | Smith et al. | Apr 2003 | A1 |
20030077326 | Newton et al. | Apr 2003 | A1 |
20030077329 | Kipp et al. | Apr 2003 | A1 |
20030079488 | Bieberich | May 2003 | A1 |
20030100936 | Altshuler et al. | May 2003 | A1 |
20030109908 | Lachenbruch et al. | Jun 2003 | A1 |
20030109910 | Lachenbruch et al. | Jun 2003 | A1 |
20030109911 | Lachenbruch et al. | Jun 2003 | A1 |
20030114885 | Nova et al. | Jun 2003 | A1 |
20030120268 | Bertolero et al. | Jun 2003 | A1 |
20030125649 | McIntosh et al. | Jul 2003 | A1 |
20030187488 | Kreindel et al. | Oct 2003 | A1 |
20030199226 | Sommer et al. | Oct 2003 | A1 |
20030199859 | Altshuler et al. | Oct 2003 | A1 |
20030220594 | Halvorson et al. | Nov 2003 | A1 |
20030220635 | Knowlton et al. | Nov 2003 | A1 |
20030220674 | Anderson et al. | Nov 2003 | A1 |
20030236487 | Knowlton | Dec 2003 | A1 |
20040002705 | Knowlton et al. | Jan 2004 | A1 |
20040006328 | Anderson | Jan 2004 | A1 |
20040009936 | Tang et al. | Jan 2004 | A1 |
20040024437 | Machold et al. | Feb 2004 | A1 |
20040030332 | Knowlton et al. | Feb 2004 | A1 |
20040034341 | Altshuler et al. | Feb 2004 | A1 |
20040039312 | Hillstead et al. | Feb 2004 | A1 |
20040044384 | Leber et al. | Mar 2004 | A1 |
20040049178 | Abboud et al. | Mar 2004 | A1 |
20040073079 | Altshuler et al. | Apr 2004 | A1 |
20040074629 | Noel | Apr 2004 | A1 |
20040077977 | Ella et al. | Apr 2004 | A1 |
20040082886 | Timpson | Apr 2004 | A1 |
20040093042 | Altshuler et al. | May 2004 | A1 |
20040104012 | Zhou et al. | Jun 2004 | A1 |
20040106867 | Eshel et al. | Jun 2004 | A1 |
20040133251 | Altshuler et al. | Jul 2004 | A1 |
20040162596 | Altshuler et al. | Aug 2004 | A1 |
20040176667 | Mihai et al. | Sep 2004 | A1 |
20040186535 | Knowlton | Sep 2004 | A1 |
20040199226 | Shadduck | Oct 2004 | A1 |
20040206365 | Knowlton | Oct 2004 | A1 |
20040210214 | Knowlton | Oct 2004 | A1 |
20040210287 | Greene | Oct 2004 | A1 |
20040215294 | Littrup et al. | Oct 2004 | A1 |
20040249427 | Nabilsi et al. | Dec 2004 | A1 |
20040259855 | Anderson et al. | Dec 2004 | A1 |
20040260209 | Ella et al. | Dec 2004 | A1 |
20040260210 | Ella et al. | Dec 2004 | A1 |
20040260211 | Maalouf | Dec 2004 | A1 |
20050033957 | Enokida | Feb 2005 | A1 |
20050049526 | Baer | Mar 2005 | A1 |
20050049543 | Anderson et al. | Mar 2005 | A1 |
20050049661 | Koffroth | Mar 2005 | A1 |
20050113725 | Masuda | May 2005 | A1 |
20050143781 | Carbunaru et al. | Jun 2005 | A1 |
20050145372 | Noel | Jul 2005 | A1 |
20050154314 | Quistgaard | Jul 2005 | A1 |
20050154431 | Quistgaard et al. | Jul 2005 | A1 |
20050159986 | Breeland et al. | Jul 2005 | A1 |
20050182462 | Chornenky et al. | Aug 2005 | A1 |
20050187495 | Quistgaard et al. | Aug 2005 | A1 |
20050187597 | Vanderschuit | Aug 2005 | A1 |
20050203446 | Takashima | Sep 2005 | A1 |
20050215987 | Slatkine | Sep 2005 | A1 |
20050222565 | Manstein | Oct 2005 | A1 |
20050251117 | Anderson et al. | Nov 2005 | A1 |
20050251120 | Anderson et al. | Nov 2005 | A1 |
20050261753 | Littrup et al. | Nov 2005 | A1 |
20050283144 | Shiono et al. | Dec 2005 | A1 |
20060030778 | Mendlein et al. | Feb 2006 | A1 |
20060035380 | Saint-Leger | Feb 2006 | A1 |
20060036300 | Kreindel | Feb 2006 | A1 |
20060041704 | Choi | Feb 2006 | A1 |
20060074313 | Slayton et al. | Apr 2006 | A1 |
20060079852 | Bubb et al. | Apr 2006 | A1 |
20060094988 | Tosaya et al. | May 2006 | A1 |
20060106836 | Masugi et al. | May 2006 | A1 |
20060122509 | Desilets | Jun 2006 | A1 |
20060189964 | Anderson et al. | Aug 2006 | A1 |
20060195168 | Dunbar et al. | Aug 2006 | A1 |
20060200063 | Munro et al. | Sep 2006 | A1 |
20060206040 | Greenberg et al. | Sep 2006 | A1 |
20060206110 | Knowlton et al. | Sep 2006 | A1 |
20060234899 | Nekmard et al. | Oct 2006 | A1 |
20060259102 | Slatkine | Nov 2006 | A1 |
20060265032 | Hennings et al. | Nov 2006 | A1 |
20060270745 | Hunt et al. | Nov 2006 | A1 |
20060293734 | Scott et al. | Dec 2006 | A1 |
20070010811 | Stern et al. | Jan 2007 | A1 |
20070010861 | Anderson et al. | Jan 2007 | A1 |
20070032561 | Lin et al. | Feb 2007 | A1 |
20070038156 | Rosenberg | Feb 2007 | A1 |
20070055156 | Desilets et al. | Mar 2007 | A1 |
20070055173 | DeLonzor et al. | Mar 2007 | A1 |
20070055179 | Deem et al. | Mar 2007 | A1 |
20070055180 | Deem et al. | Mar 2007 | A1 |
20070055181 | Deem et al. | Mar 2007 | A1 |
20070073367 | Jones et al. | Mar 2007 | A1 |
20070078502 | Weber et al. | Apr 2007 | A1 |
20070100398 | Sloan | May 2007 | A1 |
20070106342 | Schumann | May 2007 | A1 |
20070129714 | Elkins et al. | Jun 2007 | A1 |
20070135876 | Weber | Jun 2007 | A1 |
20070141265 | Thomson | Jun 2007 | A1 |
20070179482 | Anderson | Aug 2007 | A1 |
20070198071 | Ting et al. | Aug 2007 | A1 |
20070219540 | Masotti et al. | Sep 2007 | A1 |
20070239075 | Rosenberg et al. | Oct 2007 | A1 |
20070239150 | Zvuloni et al. | Oct 2007 | A1 |
20070249519 | Guha et al. | Oct 2007 | A1 |
20070255187 | Branch | Nov 2007 | A1 |
20070255274 | Stern et al. | Nov 2007 | A1 |
20070255362 | Levinson et al. | Nov 2007 | A1 |
20070265585 | Joshi et al. | Nov 2007 | A1 |
20070265614 | Stern et al. | Nov 2007 | A1 |
20070270925 | Levinson | Nov 2007 | A1 |
20070282249 | Quisenberry et al. | Dec 2007 | A1 |
20070282318 | Spooner et al. | Dec 2007 | A1 |
20080014627 | Merchant et al. | Jan 2008 | A1 |
20080046047 | Jacobs | Feb 2008 | A1 |
20080058784 | Manstein et al. | Mar 2008 | A1 |
20080077201 | Levinson et al. | Mar 2008 | A1 |
20080077202 | Levinson | Mar 2008 | A1 |
20080077211 | Levinson et al. | Mar 2008 | A1 |
20080139901 | Altshuler et al. | Jun 2008 | A1 |
20080140061 | Toubia et al. | Jun 2008 | A1 |
20080140371 | Warner | Jun 2008 | A1 |
20080183164 | Elkins et al. | Jul 2008 | A1 |
20080188915 | Mills et al. | Aug 2008 | A1 |
20080248554 | Merchant et al. | Oct 2008 | A1 |
20080269851 | Deem et al. | Oct 2008 | A1 |
20080287839 | Rosen et al. | Nov 2008 | A1 |
20080312651 | Pope et al. | Dec 2008 | A1 |
20090012434 | Anderson | Jan 2009 | A1 |
20090018623 | Levinson et al. | Jan 2009 | A1 |
20090018624 | Levinson et al. | Jan 2009 | A1 |
20090018625 | Levinson et al. | Jan 2009 | A1 |
20090018626 | Levinson et al. | Jan 2009 | A1 |
20090018627 | Levinson et al. | Jan 2009 | A1 |
20090024023 | Welches et al. | Jan 2009 | A1 |
20090076488 | Welches et al. | Mar 2009 | A1 |
20090112134 | Avni | Apr 2009 | A1 |
20090118722 | Ebbers et al. | May 2009 | A1 |
20090149929 | Levinson et al. | Jun 2009 | A1 |
20090149930 | Schenck | Jun 2009 | A1 |
20090171253 | Davenport | Jul 2009 | A1 |
20090171334 | Elkins et al. | Jul 2009 | A1 |
20090221938 | Rosenberg et al. | Sep 2009 | A1 |
20090276018 | Brader | Nov 2009 | A1 |
20090281464 | Cioanta et al. | Nov 2009 | A1 |
20090306749 | Mulindwa | Dec 2009 | A1 |
20090312676 | Rousso et al. | Dec 2009 | A1 |
20090312693 | Thapliyal et al. | Dec 2009 | A1 |
20090326621 | El-Galley | Dec 2009 | A1 |
20100015190 | Hassler | Jan 2010 | A1 |
20100028969 | Mueller et al. | Feb 2010 | A1 |
20100030306 | Edelman et al. | Feb 2010 | A1 |
20100036295 | Altshuler et al. | Feb 2010 | A1 |
20100049178 | Deem et al. | Feb 2010 | A1 |
20100081971 | Allison | Apr 2010 | A1 |
20100087806 | Da Silva et al. | Apr 2010 | A1 |
20100152824 | Allison | Jun 2010 | A1 |
20100168726 | Brookman | Jul 2010 | A1 |
20100179531 | Nebrigic et al. | Jul 2010 | A1 |
20100198064 | Perl et al. | Aug 2010 | A1 |
20100217349 | Fahey et al. | Aug 2010 | A1 |
20100268220 | Johnson et al. | Oct 2010 | A1 |
20100280582 | Baker et al. | Nov 2010 | A1 |
20110009860 | Chornenky et al. | Jan 2011 | A1 |
20110040235 | Castel | Feb 2011 | A1 |
20110040299 | Kim et al. | Feb 2011 | A1 |
20110046523 | Altshuler et al. | Feb 2011 | A1 |
20110066083 | Tosaya et al. | Mar 2011 | A1 |
20110066216 | Ting et al. | Mar 2011 | A1 |
20110077557 | Wing et al. | Mar 2011 | A1 |
20110077723 | Parish et al. | Mar 2011 | A1 |
20110112405 | Barthe et al. | May 2011 | A1 |
20110112520 | Kreindel | May 2011 | A1 |
20110144631 | Elkins et al. | Jun 2011 | A1 |
20110152849 | Baust et al. | Jun 2011 | A1 |
20110172651 | Altshuler et al. | Jul 2011 | A1 |
20110189129 | Qiu et al. | Aug 2011 | A1 |
20110196395 | Maschke | Aug 2011 | A1 |
20110196438 | Mnozil et al. | Aug 2011 | A1 |
20110202048 | Nebrigic et al. | Aug 2011 | A1 |
20110238050 | Allison et al. | Sep 2011 | A1 |
20110238051 | Levinson et al. | Sep 2011 | A1 |
20110257642 | Griggs, III | Oct 2011 | A1 |
20110300079 | Martens et al. | Dec 2011 | A1 |
20110301585 | Goulko | Dec 2011 | A1 |
20110313411 | Anderson et al. | Dec 2011 | A1 |
20110313412 | Kim et al. | Dec 2011 | A1 |
20120010609 | Deem et al. | Jan 2012 | A1 |
20120016239 | Barthe et al. | Jan 2012 | A1 |
20120022518 | Levinson | Jan 2012 | A1 |
20120022622 | Johnson et al. | Jan 2012 | A1 |
20120035475 | Barthe et al. | Feb 2012 | A1 |
20120035476 | Barthe et al. | Feb 2012 | A1 |
20120046547 | Barthe et al. | Feb 2012 | A1 |
20120053458 | Barthe et al. | Mar 2012 | A1 |
20120065629 | Elkins et al. | Mar 2012 | A1 |
20120083862 | Altshuler et al. | Apr 2012 | A1 |
20120101549 | Schumann | Apr 2012 | A1 |
20120109041 | Munz | May 2012 | A1 |
20120158100 | Schomacker | Jun 2012 | A1 |
20120209363 | Williams, III et al. | Aug 2012 | A1 |
20120239123 | Weber et al. | Sep 2012 | A1 |
20120253416 | Erez et al. | Oct 2012 | A1 |
20120259322 | Fourkas et al. | Oct 2012 | A1 |
20120277674 | Clark, III et al. | Nov 2012 | A1 |
20120310232 | Erez | Dec 2012 | A1 |
20130018236 | Altshuler et al. | Jan 2013 | A1 |
20130019374 | Schwartz | Jan 2013 | A1 |
20130066309 | Levinson | Mar 2013 | A1 |
20130073017 | Liu et al. | Mar 2013 | A1 |
20130079684 | Rosen et al. | Mar 2013 | A1 |
20130116758 | Levinson et al. | May 2013 | A1 |
20130116759 | Levinson et al. | May 2013 | A1 |
20130150844 | Deem et al. | Jun 2013 | A1 |
20130158636 | Ting et al. | Jun 2013 | A1 |
20130166003 | Johnson et al. | Jun 2013 | A1 |
20130185440 | Blau et al. | Jul 2013 | A1 |
20130190744 | Avram et al. | Jul 2013 | A1 |
20130238062 | Ron Edoute et al. | Sep 2013 | A1 |
20130245507 | Khorassani Zadeh | Sep 2013 | A1 |
20130253384 | Anderson et al. | Sep 2013 | A1 |
20130253493 | Anderson et al. | Sep 2013 | A1 |
20130253494 | Anderson et al. | Sep 2013 | A1 |
20130253495 | Anderson et al. | Sep 2013 | A1 |
20130253496 | Anderson et al. | Sep 2013 | A1 |
20130303904 | Barthe et al. | Nov 2013 | A1 |
20130303905 | Barthe et al. | Nov 2013 | A1 |
20130331914 | Lee et al. | Dec 2013 | A1 |
20140005759 | Fahey et al. | Jan 2014 | A1 |
20140005760 | Levinson et al. | Jan 2014 | A1 |
20140142469 | Britva et al. | May 2014 | A1 |
20140200487 | Ramdas et al. | Jul 2014 | A1 |
20140200488 | Seo et al. | Jul 2014 | A1 |
20140222121 | Spence et al. | Aug 2014 | A1 |
20140277219 | Nanda | Sep 2014 | A1 |
20140277302 | Weber et al. | Sep 2014 | A1 |
20140303697 | Anderson et al. | Oct 2014 | A1 |
20150209174 | Abreu | Jul 2015 | A1 |
20150216719 | DeBenedictis et al. | Aug 2015 | A1 |
20150216720 | DeBenedictis et al. | Aug 2015 | A1 |
20150216816 | O'Neil et al. | Aug 2015 | A1 |
20150223975 | Anderson et al. | Aug 2015 | A1 |
20150328077 | Levinson | Nov 2015 | A1 |
20150335468 | Rose et al. | Nov 2015 | A1 |
20150342780 | Levinson et al. | Dec 2015 | A1 |
20160051308 | Pennybacker et al. | Feb 2016 | A1 |
20160051401 | Yee et al. | Feb 2016 | A1 |
20160135985 | Anderson | May 2016 | A1 |
20160324684 | Levinson et al. | Nov 2016 | A1 |
Number | Date | Country |
---|---|---|
2011253768 | Jun 2012 | AU |
2441489 | Mar 2005 | CA |
2585214 | Oct 2007 | CA |
333982 | Nov 1958 | CH |
86200604 | Oct 1987 | CN |
2514795 | Oct 2002 | CN |
2514811 | Oct 2002 | CN |
1511503 | Jul 2004 | CN |
1741777 | Mar 2006 | CN |
1817990 | Aug 2006 | CN |
2843367 | Dec 2006 | CN |
2850584 | Dec 2006 | CN |
2850585 | Dec 2006 | CN |
200970265 | Nov 2007 | CN |
101259329 | Sep 2008 | CN |
101309657 | Nov 2008 | CN |
532976 | Sep 1931 | DE |
2851602 | Jun 1980 | DE |
4213584 | Nov 1992 | DE |
4224595 | Jan 1994 | DE |
4238291 | May 1994 | DE |
4445627 | Jun 1996 | DE |
19800416 | Jul 1999 | DE |
0263069 | Apr 1988 | EP |
0397043 | Nov 1990 | EP |
0406244 | Jan 1991 | EP |
0598824 | Jun 1994 | EP |
1030611 | Aug 2000 | EP |
1201266 | May 2002 | EP |
1568395 | Aug 2005 | EP |
2260801 | Dec 2010 | EP |
2289598 | Mar 2011 | EP |
2527005 | Nov 2012 | EP |
854937 | Apr 1940 | FR |
2744358 | Aug 1997 | FR |
2745935 | Sep 1997 | FR |
2767476 | Feb 1999 | FR |
2776920 | Oct 1999 | FR |
2789893 | Aug 2000 | FR |
2805989 | Sep 2001 | FR |
387960 | Feb 1933 | GB |
2120944 | Dec 1983 | GB |
2248183 | Apr 1992 | GB |
2263872 | Aug 1993 | GB |
2286660 | Aug 1995 | GB |
2323659 | Sep 1998 | GB |
58187454 | Nov 1983 | JP |
63076895 | Apr 1988 | JP |
S6382936 | Apr 1988 | JP |
01223961 | Sep 1989 | JP |
03051964 | Mar 1991 | JP |
3259975 | Nov 1991 | JP |
4093597 | Mar 1992 | JP |
H06261933 | Sep 1994 | JP |
6282977 | Oct 1994 | JP |
7194666 | Aug 1995 | JP |
7268274 | Oct 1995 | JP |
09164163 | Jun 1997 | JP |
10216169 | Aug 1998 | JP |
10223961 | Aug 1998 | JP |
2000503154 | Mar 2000 | JP |
3065657 | Jul 2000 | JP |
2001046416 | Feb 2001 | JP |
2002125993 | May 2002 | JP |
2002224051 | Aug 2002 | JP |
2002282295 | Oct 2002 | JP |
2002290397 | Oct 2002 | JP |
2002543668 | Dec 2002 | JP |
2003190201 | Jul 2003 | JP |
2004013600 | Jan 2004 | JP |
2004073812 | Mar 2004 | JP |
2004159666 | Jun 2004 | JP |
2005039790 | Feb 2005 | JP |
3655820 | Mar 2005 | JP |
200565984 | Mar 2005 | JP |
2005110755 | Apr 2005 | JP |
2005509977 | Apr 2005 | JP |
2005520608 | Jul 2005 | JP |
2005237908 | Sep 2005 | JP |
2005323716 | Nov 2005 | JP |
2006026001 | Feb 2006 | JP |
2006130055 | May 2006 | JP |
2006520949 | Sep 2006 | JP |
2007270459 | Oct 2007 | JP |
2008532591 | Aug 2008 | JP |
2009515232 | Apr 2009 | JP |
2009189757 | Aug 2009 | JP |
200173222 | Dec 1999 | KR |
102004009450 | Nov 2004 | KR |
20090000258 | Jan 2009 | KR |
1020130043299 | Apr 2013 | KR |
1020140038165 | Mar 2014 | KR |
2036667 01 | Jun 1995 | RU |
532976 | Nov 1978 | SU |
0476644 | Feb 2002 | TW |
WO-8503216 | Aug 1985 | WO |
9114417 | Oct 1991 | WO |
WO-9404116 | Mar 1994 | WO |
9623447 | Aug 1996 | WO |
9626693 | Sep 1996 | WO |
WO-9636293 | Nov 1996 | WO |
WO-9637158 | Nov 1996 | WO |
9704832 | Feb 1997 | WO |
WO-9705828 | Feb 1997 | WO |
WO-9722262 | Jun 1997 | WO |
9724088 | Jul 1997 | WO |
WO-9725798 | Jul 1997 | WO |
9748440 | Dec 1997 | WO |
9829134 | Jul 1998 | WO |
9831321 | Jul 1998 | WO |
WO-9841157 | Sep 1998 | WO |
WO-9841156 | Sep 1998 | WO |
9909928 | Mar 1999 | WO |
9916502 | Apr 1999 | WO |
WO-9938469 | Aug 1999 | WO |
9949937 | Oct 1999 | WO |
WO-0044346 | Aug 2000 | WO |
WO-0044349 | Aug 2000 | WO |
WO-0065770 | Nov 2000 | WO |
WO-0067685 | Nov 2000 | WO |
0100269 | Jan 2001 | WO |
0113989 | Mar 2001 | WO |
WO-0114012 | Mar 2001 | WO |
0134048 | May 2001 | WO |
WO-0205736 | Jan 2002 | WO |
WO-02102921 | Dec 2002 | WO |
WO-03007859 | Jan 2003 | WO |
WO-03078596 | Sep 2003 | WO |
03079916 | Oct 2003 | WO |
WO-2004000098 | Dec 2003 | WO |
WO-2004080279 | Sep 2004 | WO |
WO-2004090939 | Oct 2004 | WO |
WO-2005033957 | Apr 2005 | WO |
WO-2005046540 | May 2005 | WO |
2005060354 | Jul 2005 | WO |
WO-2005096979 | Oct 2005 | WO |
2005112815 | Dec 2005 | WO |
WO-2006066226 | Jun 2006 | WO |
WO-2006094348 | Sep 2006 | WO |
WO-2006106836 | Oct 2006 | WO |
2006116603 | Nov 2006 | WO |
WO-2006127467 | Nov 2006 | WO |
WO-2007012083 | Jan 2007 | WO |
2007028975 | Mar 2007 | WO |
WO-2007041642 | Apr 2007 | WO |
WO-2007101039 | Sep 2007 | WO |
WO-2007127924 | Nov 2007 | WO |
2007145421 | Dec 2007 | WO |
2007145422 | Dec 2007 | WO |
2008006018 | Jan 2008 | WO |
2008039556 | Apr 2008 | WO |
WO-2008039557 | Apr 2008 | WO |
2008055243 | May 2008 | WO |
WO-2008143678 | Nov 2008 | WO |
WO-2009011708 | Jan 2009 | WO |
WO-2009026471 | Feb 2009 | WO |
WO-2010077841 | Jul 2010 | WO |
WO-2010127315 | Nov 2010 | WO |
WO-2012012296 | Jan 2012 | WO |
WO-2012103242 | Aug 2012 | WO |
2013013059 | Jan 2013 | WO |
2013075006 | May 2013 | WO |
2013075016 | May 2013 | WO |
2013190337 | Dec 2013 | WO |
Entry |
---|
Bohm et al., “Saline-enhanced radiofrequency ablation of breast tissue: an in vitro feasibility study,” Invest Radiol, 2000, pp. 149-57, vol. 35—issue (3). |
European Search Report, European Application No. EP07758558.6; Applicant: Zeltiq Aesthetics, Inc.; dated Jul. 20, 2007, 4 pages. |
European Search Report, European Patent Application No. 10167756.5, Applicant: The General Hospital Corporation, dated Aug. 31, 2010, 6 pages. |
European Search Report, Eurpean Patent Application No. EP07761461; Applicant: Zeltiq Aesthetics, Inc., dated Apr. 25, 2012, 9 pages. |
European Search Report, Supplement, European Patent Application No. EP08798416.7, Applicant: Zeltiq Aesthetics, Inc., dated Jan. 12, 2012, 7 pages. |
European Search Report, Supplement, European Patent Application No. EP09836823, Applicant: Zeltiq Aesthetics, Inc., dated May 15, 2012, 5 pages. |
Final Office Action; U.S. Appl. No. 11/435,502; dated Mar. 29, 2010, 11 pages. |
Final Office Action; U.S. Appl. No. 11/528,225; dated Dec. 29, 2010, 9 pages. |
Final Office Action; U.S. Appl. No. 11/558,046; dated Mar. 30, 2011, 17 pages. |
Final Office Action; U.S. Appl. No. 11/741,271; dated Jul. 19, 2012, 8 pages. |
Final Office Action; U.S. Appl. No. 11/750,953; dated Jul. 5, 2012, 11 pages. |
Hale et al., “Influence of chronic heat exposure and prolonged food deprivation on execretion of magnesium, phosphorus, calcium, hydrogen ion & ketones,” Aerosp Med, 1968, pp. 919-26, vol. 39—issue (9). |
International Search Report and Written Opinion for PCT/US2005/045988; Applicant: The General Hospital Corporation; dated Apr. 25, 2006, 14 pages. |
International Search Report and Written Opinion for PCT/US2007/062508; Applicant: Juniper Medical, Inc.; dated Jul. 20, 2007, 13 pages. |
International Search Report and Written Opinion for PCT/US2009/067973; Applicant: Zeltiq Aesthetics, Inc.; dated Feb. 18, 2010, 10 pages. |
International Search Report and Written Opinion for PCT/US2010/033290; Applicant: Zeltiq Aesthetics, Inc.; dated Feb. 25, 2011, 12 pages. |
International Search Report and Written Opinion for PCT/US2011/022112; Applicant: Zeltiq Aesthetics, Inc.; dated Mar. 18, 2011, 11 pages. |
International Search Report and Written Opinion for PCT/US2011/022444; Applicant: Zeltiq Aesthetics, Inc., dated Mar. 29, 2011, 14 pages. |
International Search Report and Written Opinion for PCT/US2012/022585; dated May 18, 2012, 14 pages. |
Koska, J. et al., “Endocrine Regulation of Subcutaneous Fat Metabolism During Cold Exposure in Humans,” Ann N.Y. Acad, Sci., 967:500-05, 2002. |
Kundu et al., “Breath acetone analyzer: diagnostic tool to monitor dietary fat loss,” Clin Chem, 1993, pp. 87-92, vol. 39, issue (1). |
Laugier, et al., “In Vivo Results with a New Device for Ultrasonic Monitoring of Pig Skin Cryosurgery: The Echographic Cryoprobe,” The society for Investigative Dermatology, Inc., vol. 111(2), Aug. 1998. |
Lidagoster, MD et al., “Comparison of Autologous Fat Transfer in Fresh, Refrigerated, and Frozen Specimens: An Animal Model Presented,” at the 16th Annual Meeting of the Northeastern Society of Plastic Surgeons: Burlington, VT, 1999, pp. 512-515. |
Merrill, Tom, “A Chill to the Heart: A System to Deliver Local Hypothermia Could One Day Improve the Lives of Heart-Attack Patients,” Mechanical Engineering Magazine, Oct. 2010 (10 pages). |
Murphy, J.V. et al., “Frostbite: Pathogenesis and Treatment,” The Journal of Trauma: Injury, Infection, and Critical Care, 48(1):171-178, 2000. |
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated Jan. 25, 2006, 6 pages. |
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated May 30, 2007, 8 pages. |
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated Jul. 22, 2005, 6 pages. |
Non-Final Office Action; U.S. Appl. No. 11/528,189; dated Apr. 6, 2012, 9 pages. |
Non-Final Office Action; U.S. Appl. No. 11/528,225; dated Apr. 12, 2010, 11 pages. |
Non-Final Office Action; U.S. Appl. No. 11/528,225; dated Aug. 3, 2011, 11 pages. |
Non-Final Office Action; U.S. Appl. No. 11/558,046; dated Jul. 12, 2010, 14 pages. |
Non-Final Office Action; U.S. Appl. No. 11/741,271; dated Jul. 12, 2010, 9 pages. |
Non-Final Office Action; U.S. Appl. No. 11/777,992; dated Jun. 22, 2012, 5 pages. |
Non-Final Office Action; U.S. Appl. No. 12/565,613; dated Sep. 23, 2011, 32 pages. |
Non-Final Office Action; U.S. Appl. No. 12/942,852; dated Mar. 7, 2011, 6 pages. |
Non-Final Office Action; U.S. Appl. No. 12/942,852; dated Jun. 30, 2011, 10 pages. |
Pre-Interview Office Action; U.S. Appl. No. 11/434,478; dated May 6, 2010, 4 pages. |
Rabi, “Metabolic adaptations in brown adipose tissue of the hamster in extreme ambient temperatures,” American Journal of Physiology 231, 153-160 (1976). |
Renold, A.E., “Adipose Tissue,” Handbook of Physiology, Chapter 15:170-76, 1965. |
Rubinsky, “Cryosurgery: advances in the application of low temperatures to medicine,” Int. J. Refrig. 190-199 (1991). |
Wang et al., “Cryopreservation of cell/hydrogel constructs based on a new cell-assembling technique”, Sep. 5, 2009, 40 pages. |
Ardevol, “Cooling rates of tissue samples during freezing with liquid nitrogen,” J. of Biochem and Biophysical Methods, 27, 77-86 (1993). |
Bondei, E. et al., “Disorders of Subcutaneous Tissue (Cold Panniculitis),” Dermatology in General Medicine, Chapter 108, Section 16: 1333-1334, 1993. |
Burge, S.M. et al., “Hair Follicle Destruction and Regeneration in Guinea Pig Skin after Cutaneous Freeze Injury,” Cryobiology, 27(2): 153-163, 1990. |
Coban, “Ischemia-Reperfusion Injury of Adipofascial Tissue: An Experimental Study Evaluating early Histologic and Biochemical Alterations in Rats,” Mediators of Inflammation, 2005, 5, 304-308. |
Donski et al., “The Effects of Cooling no Experimental Free Flap Survival,” Brit J Plas Surg, 1980, pp. 353-360, vol. 33. |
Duncan, W.C. et al., “Cold Panniculitis,” Arch. Derm., 94:722-24, 1966. |
Epstein, E.H. et al., “Popsicle Panniculitis,” The New England Journal of Medicine, 282(17):996-67, 1970. |
Final Office Action; U.S. Appl. No. 10/391,221; dated Aug. 24, 2006, 4 pages. |
Final Office Action; U.S. Appl. No. 11/016,196; dated Mar. 23, 2010, 12 pages. |
Gage, “Current Progress in Cryosurgery,” Cryobiology 25, 483-486 (1988). |
Heller-Page et al., “Temperature-dependent skin disorders,” Journal of the American Academy of Dermatology, May 1988, vol. 18, No. 5, Pt 1, pp. 1003-1019. |
Hemmingsson, “Attenuation in Human muscle and Fat Tissue in Vivo and in Vitro,” Acta Radiologica Diagnosis 23, 149-151 (1982). |
Henry et al.,“Les Dermatoses Hivernales,” Rev Med Liege, 1999, 54:11, 864-866. [Abstract Attached]. |
Holman, “Variation in cryolesion penetration due to probe size and tissue thermal conductivity,” Ann. Thorac. Surg. 53, 123-126 (1992). |
Hong, “Patterns of Ice Formulation in Normal and Malignant Breast Tissue,” Cryobiology 31, 109-120 (1994). |
International Search Report and Written Opinion for PCT/US2007/023492; Applicant: Zeltiq Aesthetics, Inc.; dated May 15, 2008, 7 pages. |
International Search Report and Written Opinion for PCT/US2007/064016; Applicant: Juniper Medical, Inc.; dated Jul. 20, 2007, 13 pages. |
International Search Report and Written Opinion for PCT/US2007/064017; Applicant: Juniper Medical, Inc.; dated Oct. 26, 2007, 16 pages. |
International Search Report and Written Opinion for PCT/US2007/064018; Applicant: Juniper Medical, Inc.; dated Jul. 26, 2007, 13 pages. |
International Search Report and Written Opinion for PCT/US2007/067638; Applicant: Juniper Medical, Inc.; dated Jan. 10, 2008, 11 pages. |
International Search Report and Written Opinion for PCT/US2007/069694; Applicant: Juniper Medical, Inc.; dated Nov. 23, 2007, 12 pages. |
International Search Report and Written Opinion for PCT/US2007/075935; Applicant: Zeltiq Aesthetics, Inc.; dated Apr. 10, 2008, 12 pages. |
International Search Report and Written Opinion for PCT/US2007/083255; Applicant: Zeltiq Aesthetics, Inc.; dated Aug. 11, 2008, 8 pages. |
International Search Report and Written Opinion for PCT/US2008/073930; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 7, 2008, 10 pages. |
International Search Report and Written Opinion for PCT/US2009/058088; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 20, 2009, 14 pages. |
Kellum, R.E. et al., “Sclerema Neonatorum: Report of Case and Analysis of Subcutaneous and Epidermal-Dermal Lipids by Chromatographic Methods,” Arch. Derm., 97:372-80, 1968. |
Kundu et al., “Novel solid-phase assay of ketone bodies in urine,” Clin Chem, 1991, pp. 1565-1569, vol. 37—issue (9). |
Kuroda et al., “Thermal distribution of radio-frequency inductive hyperthermia using an inductive aperture-type applicator: evaluation of the effect of tumour size and depth,” Med Biol Eng Comput, 1999, pp. 285-290, vol. 37—issue (3). |
Levchenko, et al., “Effect of dehydration on lipid metabolism,” WMJ, 1978, pp. 95-97, vol. 50—issue (1). |
Liu, A.Y.C. et al., “Transient Cold Shock Induces the Heat Shock Response upon Recovery at 37 C in Human Cells,” J. Biol. Chem., May 20, 1994, 269(20), 14768-14775. |
Lvova, “Lipid levels and lipid peroxidation in frog tissues during hypothermia and hibernation,” WMJ, 1990, pp. 65-70, vol. 62—issue (1). |
Maize, J.C., “Panniculitis,” Cutaneous Pathology, Chapter 13:327-344, 1998. |
Malcolm, G. et al., “Fatty Acid Composition of Adipose Tissue in Humans: Differences between Subcutaneous Sites,” Am J Clin. Nutr., 50(2):288-91, 1989. |
Moschella, S.L. et al., “Diseases of the Subcutaneous Tissue,” Derm., Section 2:1169-1181, 1985. |
Nagao et al., “Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men a double-blind controlled trial,” J Nutr, 2000, pp. 792-797, vol. 130—issue (4). |
Nagore et al., “Lipoatrophia semicircularis-a traumatic panniculitis: Report of seven cases and review of the literature,” Journal of the American Academy of Dermatology, Nov. 1998, 39:879-81. |
Nielsen, “Thermoregulation in Rest and Exercise,” Acta Phys Scan Supp, 1969, pp. 6-74, vol. 323. |
Nishikawa, “Ultrastructural Changes and Lipid Peroxidation in Rat Adipomusculocutaneous Flap Isotransplants after Normothermic Storage and Reperfusion,” Transplantation, 1992, 54, 795-801. |
Non-Final Office Action; U.S. Appl. No. 11/016,196; dated Apr. 22, 2008, 11 pages. |
Non-Final Office Action; U.S. Appl. No. 11/016,196; dated Sep. 25, 2009, 8 pages. |
Non-Final Office Action; U.S. Appl. No. 11/359,092; dated Nov. 19, 2009, 13 pages. |
Non-Final Office Action; U.S. Appl. No. 11/435,502; dated Jul. 17, 2009, 10 pages. |
Pease, “An Integrated Probe for Magnetic Resonance Imaging Monitored Skin Cryosurgery,” Journal of Biomedical Engineering 117, 59-63, (1995). |
Pech, “Attenuation values, volume changes and artifacts in tissue due to freezing,” Acta Radiologica 6, 779-782 (1987). |
Peterson et al., “Bilateral Fat Necrosis of the Scrotum, Urology Service, Department of Surgery, Dermatology Service, Department of Medicine and Department of Pediatrics,” Letterman Army Medical Center, Journal of Urology, 1976, pp. 825-826, vol. 116, The Williams & Wilkins Co. |
Phinney, S.D. et al., “Human Subcutaneous Adipose Tissue Shows Site-Specific Differences in Fatty Acid Composition,” Am J. Clin. Nutr., 60:725-29, 1994. |
Schoning, et al., “Experimental Frostbite: Freezing Times, Rewarming Times, and Lowest Temperatures of Pig Skin Exposed to Chilled Air,” Cryobiology, 1990, pp. 189-193, 27. |
Shephard, “Adaptation to Exercise in the Cold,” Sports Medicine, 1985, 2:59-71. |
Wharton et al., “Cold acclimation and cryoprotectants in a freeze-tolerant Antarctic nematode, Panagrolaimus davidi,” Mar. 7, 2000, 2 pages. |
Winkler et al., “Gene Transfer in Laboratory Fish: Model Organisms for the Analysis of Gene Function,” Transgenic Animals, 1997, pp. 387-395. |
Young, H.E. et al., “Isolation of Embryonic Chick Myosatellite and Pluripotent Stem Cells, ” J. Tiss. Cult. Meth., 14:85-92, 1992. |
International Preliminary Examining Authority Written Opinion for PCT/US2007/67638; Application Levinson et al. dated Jun. 8, 2010. |
International Preliminary Examining Authority Written Opinion for PCT/US2007/67638; Application Levinson et al. dated Sep. 21, 2010, 7 pages. |
International Search Report and Written Opinion for PCT/US2011/044270; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 21, 2011. 9 pages. |
Non-Final Office Action; U.S. Appl. No. 12/337,544; dated Mar. 30, 2012, 13 pgs. |
Pierard, G.E., Nizet, J.L., Pierard-Franchimont, C., “Cellulite: From Standing Fat Herniation to Hypodermal Stretch Marks,” Am. J. Dermatol. 22:1, 34-37, 2000. |
Pope, “Selective Firbous Septae Heating”, Thermage Article, Feb. 2005, 7pgs. |
Quinn, P.J., “A Lipid Phase Separation Model of Low Temperature Damage to Biological Membranes” Cryobiology, 22: 128-147, 1985. |
Sigma-Aldrich “Polyethylene glycol and Polyethylene oxide,” http://www.sigmaaldrich.com/materials-science/materialscience-; products.htmi?TablePage=2020411 0, accessed Oct. 19, 2012. |
European Search Report; Application No. EP10770461; dated Aug. 31, 2012; Applicant: Zeltiq Aesthetics, Inc. 5 pgs. |
Non-Final Office Action; U.S. Appl. No. 12/840,235; dated Apr. 11, 2013; 9 pages. |
Manstein et al. “A Novel Cryotherapy Method of Non-invasive, Selective Lipolysis” LasersSurg.Med 40:S20 p. 104 (2008). |
Manstein et al.“Selective Cryolysis: A Novel Method of Non-Invasive Fat Removal”, LasersSurg.Med. 40:595-604 (2008). |
Nagle W.A., Soloff, B.L., Moss, A.J. Jr., Henle K.J. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures” Cryobiology 27, 439-451 (1990). |
Narins, “Non-Surgical Radiofrequency Facelift”, 2003, 495-500, 6 pgs. |
Mazur, P. “Cryobiology: the Freezing of Biological Systems” Science, 68: 939-949 (1970). |
Rubinsky, B., “Principles of Low Temperature Preservation” Heart Failure Reviews, 8, 277-284 (2003). |
Thermage, News Release, “Study Published in Facial Plastic Surgery Journal Finds Selective Heating of Fibrous Septae Key to Success and Safety of Thermage ThermoCool System”, Jun. 20, 2005, 2 pages. |
Vallerand, A.L., Zamecnik. J., Jones, P.J.H. Jacobs, I. “Cold Stress Increases Lipolysis, FFA RA and TG/FFA Cycling in Humans” Aviation, Space, and Environmental Medicine 70, 42-50 (1999). |
Rossi, “Cellulite: a Review” 2000, 251-262, 12 pgs. |
“ThermaCool Monopolar Capacitive Radiofrequency”,The one choice for nonabliative tissue tightening and contouring, Tech Brochure, Nov. 30, 2005, 8 pgs. |
“So-Called Cellulite: An Invetnted Disease”, Nurnberger, Journal Title: Journal of dermatologic surgery and oncology, Mar. 1978, 14 pgs. |
“Effect of Controlled Volumetric Tissue Heating with Radiorequency on Cellulite and the Subcutaneous Tissue of the Bottocks and Thighs”. Del Pino, 2006, 9 pgs. |
Mayoral, “Skin Tightening with a Combinded Unipolar and Bipolar Radiofrequency Device” , 2007 Journal of Drugs in Dermatology, 4 pgs. |
Becker, “Local Tempertature Rises Influence In Vivo Electroporation Pore Development: A Numerical Stratum Corneum Lipid Phase Transition Model”, Oct. 2007, 10 pgs. |
Miklavcic, “Electroporation-Based Technologies and Treatments”, 2010 236:1-2, 2 pgs. |
Nanda, “Studies on electroporation of thermally and chemically treated human erythocytes”, May 28, 1993 in revised form Mar. 7, 1994, 6 pgs. |
BioMedical Engineering OnLine, “High-Frequency Irreversible electroporation (H-FIRE) for non-thermal ablation without muscle contraction”, Nov. 21, 2011, 21 pgs. |
Al-Sakere, “Tumor Ablation with Irreversible Electroporation”, Nov. 2007, Issue 11, 8 pgs. |
Non-Final Office Action, U.S. Appl. No. 13/616,497, dated Jun. 28, 2013, 38 pages. |
PubMed, “Effects of thermal shocks on interleukin-1 levels and heat shock protein 72 (HSP72) expression in normal human keratinocytes”, Arch Dermatol Res. 1992; 284(7): 414-7. |
PubMed, “Cold shock induces the synthesis of stress proteins in human kerantinocytes”, Holland DB. Aug. 1993; 101(2): 196-9. |
Aguilar et al., “Modeling Cryogenic Spray Temperature and Evaporation Rate Based on Single-Droplet Analysis,” Eighth International Conference on Liquid Atomization and Spray Systems, Pasadena, CA, USA, Jul. 2000, 7 pages. |
Alster, T. et al., “Cellulite Treatment Using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic and Laser Therapy, vol. 7, 2005, pp. 81-85. |
Ardevol et al., “Cooling Rates of Tissue Samples During Freezing with Liquid Nitrogen,” Journal of Biochemical and Biophysical Methods, 27, 1993, pp. 77-86. |
Duck, F. A., Physical Properties of Tissue, Academic Press Ltd., chapters 4 & 5, 1990, pp. 73-165. |
Fournier, L. et al. “Lattice Model for the Kinetics of Rupture of Fluid Bilayer Membranes,” Physical Review, vol. 67, 2003, pp. 051908-1-051908-11. |
Gabriel, S. et al., “The Dielectric Properties of Biological Tissues: II. Measurements in the Frequency Range 10 Hz to 20 GHz,” Physics in Medicine and Biology, vol. 41, 1996, pp. 2251-2269. |
Isambert, H. “Understanding the Electroporation of Cells and Artificial Bilayer Membranes,” Physical Review Letters, vol. 80, No. 15, 1998, pp. 3404-3707. |
Peterson, L. J. et al., “Bilateral Fat Necrosis of the Scrotum,” Journal of Urology, vol. 116, 1976, pp. 825-826. |
Saleh, K.Y. et al., “Two-Dimensional Ultrasound Phased Array Design for Tissue Ablation for Treatment of Benign Prostatic Hyperplasia,” International Journal of Hyperthermia, vol. 20, No. 1, Feb. 2004, pp. 7-31. |
Schoning, P. et al., “Experimental Frostbite: Freezing Times, Rewarming Times, and Lowest Temperatures of Pig Skin Exposed to Chilled Air,” Cryobiology 27, 1990, pp. 189-193. |
Zouboulis, C. C. et al., “Current Developments and Uses of Cryosurgery in the Treatment of Keloids and Hypertrophic Scars,” Wound Repair and Regeneration, vol. 10, No. 2, 2002, pp. 98-102. |
Hernan, P. et al., “Study for the evaluation of the efficacy of Lipocryolysis (EEEL)”, Nov. 30, 2011. |
Hernan, R. P., “A Study to Evaluate the Action of Lipocryolysis”, 33(3) CryoLellers, 2012, pp. 176-180. |
Jalian, H. R. et al., “Cryolipolysis: A Historical Perspective and Current Clinical Practice”, 32(1) Semin. Cutan. Med. Surg., 2013, pp. 31-34. |
Zelickson, B. et al., “Cryolipolysis for Noninvasive Fat Cell Destruction: Initial Results from a Pig Model”, 35 Dermatol. Sug., 2009, pp. 1-9. |
Number | Date | Country | |
---|---|---|---|
20130245731 A1 | Sep 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12337544 | Dec 2008 | US |
Child | 13888168 | US |